The term "blue chip" originated from poker, where blue chips were the highest denomination of chips used in the game.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Dr. Altagrace Hanley, medical director at La Boussole Medical Spa & Wellness Center, has achieved board certification in obesity medicine. La Boussole's program includes advanced options such as GLP-1 ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

Pharmacists say they are aware of people being wrongly prescribed the drugs who have previously had eating disorders, or ...

We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

After the market close on Thursday, Twilio introduced new financial expectations in a regulatory filing. The company said it ...